Quantoom Biosciences
Greater access and autonomy through innovation in bioproduction
We are on a mission to remove the barriers to making mRNA-based vaccines & therapeutics,
at every stage from sequence up to mass production.
Who We Are
Quantoom Biosciences, a Univercells company, is reinventing mRNA production by developing an RNA Platform that encompasses DNA and RNA manufacturing and formulation, along with critical reagent supply, from sequence to large scale production.
We are a team of scientists, engineers and clinicians committed to solving some of the biggest DNA and RNA production challenges facing vaccines and therapeutics, by delivering greater access and autonomy to mRNA technology.
In December 2021, we expanded our team with the acquisition of SynHelix which specializes in synthetic DNA and enzyme engineering.
Our facilities are strategically located in Belgium and France, in the heart of Europe, benefiting from an exceptional biotech ecosystem.
Who We Are
Quantoom Biosciences, a Univercells company, is reinventing mRNA production by developing an RNA Platform that encompasses DNA and RNA manufacturing and formulation, along with critical reagent supply, from sequence to large scale production.
We are a team of scientists, engineers and clinicians committed to solving some of the biggest DNA and RNA production challenges facing vaccines and therapeutics, by delivering greater access and autonomy to mRNA technology.
In December 2021, we expanded our team with the acquisition of SynHelix which specializes in synthetic DNA and enzyme engineering.
Our facilities are strategically located in Belgium and France, in the heart of Europe, benefiting from an exceptional biotech ecosystem.
what we do
At Quantoom Biosciences, we are bringing radical innovation to the way mRNA is produced in any research lab, biotech biopharma and CDMO. We support our partners early on with sequence design & candidate screening up to (pre-)clinical development toward a successful mRNA product.
Our technologies are based on our Intensification and chaining engineering principles that deliver small footprint, automated and cost-effective bioproduction technologies.
More specifically, we have developed:
- A benchtop DNA system to amplify any linearized plasmid with the gene of interest as a base for RNA synthesis
- A benchtop research-grade RNA system for screening and to provide very small-scale batches of mRNA (typically µg-scale for pre-clinical applications)
- A small footprint GMP-grade RNA production system able to seamlessly scale up from clinical scale up to commercial mass production
- A Formulation system based on microfluidics to blend the RNA sequence in a LNP-based delivery vehicle
- Selected reagents that are critical to the process
what we do
At Quantoom Biosciences, we are bringing radical innovation to the way mRNA is produced in any research lab, biotech biopharma and CDMO. We support our partners early on with sequence design & candidate screening up to (pre-)clinical development toward a successful mRNA product.
Our technologies are based on our Intensification and chaining engineering principles that deliver small footprint, automated and cost-effective bioproduction technologies.
More specifically, we have developed:
- A benchtop DNA system to amplify any linearized plasmid with the gene of interest as a base for RNA synthesis
- A benchtop research-grade RNA system for screening and to provide very small-scale batches of mRNA (typically µg-scale for pre-clinical applications)
- A small footprint GMP-grade RNA production system able to seamlessly scale up from clinical scale up to commercial mass production
- A Formulation system based on microfluidics to blend the RNA sequence in a LNP-based delivery vehicle
- Selected reagents that are critical to the process
Our GMP-grade RNA Production System
We designed our RNA Production System with end users’ needs in mind, creating a radically different manufacturing technology with two features at its core.
- Intensification & chaining: We can manufacture mRNA at a wide range of capacities thanks to our sequential-continuous production mode at milliliter-scale. This includes IVT and mRNA purification, to deliver purified naked RNA
- Tunable generic process: We have redesigned the production process and validated it for mRNA and saRNA. The process is adaptable and able to take sequence specificities into consideration.
These features deliver a set of benefits for mRNA drug developers;
-
1
No scale-up needed (pre-)clinical development is already at the final scale, which accelerates your process & product development
-
2
Single small footprint system that integrates all process steps - no need to invest in a suite of equipment
-
3
Generic process that is adaptable to your specific RNA construct both for transcription and purification, with polishing options
-
4
Reduced CoGs thanks to minimal labor & RNA expertise required
-
5
In vivo validated with multiple RNA constructs to de-risk your product development
Up to 20 g per day (5 kg per year) of purified mRNA per system
Up to 100 million doses (50 µg) per year
Our GMP-grade RNA Production System
We designed our RNA Production System with end users’ needs in mind, creating a radically different manufacturing technology with two features at its core.
- Intensification & chaining: We can manufacture mRNA at a wide range of capacities thanks to our sequential-continuous production mode at milliliter-scale. This includes IVT and mRNA purification, to deliver purified naked RNA
- Tunable generic process: We have redesigned the production process and validated it for mRNA and saRNA. The process is adaptable and able to take sequence specificities into consideration.
These features deliver a set of benefits for mRNA drug developers;
-
1
No scale-up needed (pre-)clinical development is already at the final scale, which accelerates your process & product development
-
2
Single small footprint system that integrates all process steps - no need to invest in a suite of equipment
-
3
Generic process that is adaptable to your specific RNA construct both for transcription and purification, with polishing options
-
4
Reduced CoGs thanks to minimal labor & RNA expertise required
-
5
In vivo validated with multiple RNA constructs to de-risk your product development
- Up to 20 g per day (5 kg per year) of purified mRNA per system
- Up to 100 million doses (50 µg) per year
What makes us different
We deliver access and autonomy through innovation
- Process intensification and chaining with automated operations in a small footprint system
- Integration of critical components into our supply chain (such as DNA synthesis)
- Clinical-validation of platforms with (pre-) clinical studies, proving comparability
- Open access, independent licensing of desired drug product
- Secured supply of critical input materials for your operations
- Low set-up and routine cost requirements
- Eased technology transfer, limited know-how requirements to operate the platforms
- Scalability by design to seamlessly grow from lab to mass production
- Highly flexible platforms fit for a wide range of therapeutic applications
- GMP certified allowing production for clinical studies and commercialization
- Clinically-validated systems to focus your efforts on drug development
What makes us different
We deliver access and autonomy through innovation
- Process intensification and chaining with automated operations in a small footprint system
- Integration of critical components into our supply chain (such as DNA synthesis)
- Clinical-validation of platforms with (pre-) clinical studies, proving comparability
- Open access, independent licensing of desired drug product
- Secured supply of critical input materials for your operations
- Low set-up and routine cost requirements
- Eased technology transfer, limited know-how requirements to operate the platforms
- Scalability by design to seamlessly grow from lab to mass production
- Highly flexible platforms fit for a wide range of therapeutic applications
- GMP certified allowing production for clinical studies and commercialization
- Clinically-validated systems to focus your efforts on drug development
Enabling more organisations to explore a wider range of
product development opportunities to get to treatments faster.
Enabling more organisations to explore a wider range of product development opportunities to get to treatments faster.
Our Team
Our team consists of international experts whose talent, experience and commitment
make the company a key player in therapeutic development and biomanufacturing.
Management Team
José Castillo
Chief Executive Officer
(and Univercells Co-Founder)
Kristof Vandekerckhove
Chief Scientific Officer & Head of Research BE
Yves Ghislain
Head of Technical Development & Operations
Conor Cahill
Head of Product Development
Irina Gbalou
Head of Research FR
Guillaume Roelandts
Head of Commercial Operations
Rachana Talwar
Head of PMO & Chief of Staff
